Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Hasina Masha Aziz
 -- 2223 2022-04-16 16:48:49 |
2 Improvements. The record is based on: J. Clin. Med. 2022; 11(7): 1912 (cited parts of a paper).
Paweł Tomasz Matusik
+ 13 word(s) 2236 2022-04-16 23:40:12 | |
3 format correct
Catherine Yang
 -8 word(s) 2228 2022-04-18 04:17:49 | |
4 format correct
Catherine Yang
 Meta information modification 2228 2022-04-18 04:20:17 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Aziz, H.; , .; Matusik, P. Pathogenesis and Management of Brugada Syndrome. Encyclopedia. Available online: https://encyclopedia.pub/entry/21844 (accessed on 03 July 2024).
Aziz H,  , Matusik P. Pathogenesis and Management of Brugada Syndrome. Encyclopedia. Available at: https://encyclopedia.pub/entry/21844. Accessed July 03, 2024.
Aziz, Hasina, , Paweł Matusik. "Pathogenesis and Management of Brugada Syndrome" Encyclopedia, https://encyclopedia.pub/entry/21844 (accessed July 03, 2024).
Aziz, H., , ., & Matusik, P. (2022, April 16). Pathogenesis and Management of Brugada Syndrome. In Encyclopedia. https://encyclopedia.pub/entry/21844
Aziz, Hasina, et al. "Pathogenesis and Management of Brugada Syndrome." Encyclopedia. Web. 16 April, 2022.
Pathogenesis and Management of Brugada Syndrome
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11071912

Brugada syndrome (BrS) is a primary electrical disease associated with arrhythmias and an elevated risk of sudden cardiac death (SCD). It was described by Pedro and Josep Brugada in 1992 as a syndrome comprised of “right bundle branch block, persistent ST segment elevation and SCD”. The prevalence of BrS electrocardiogram (ECG) patterns differs largely among various regions and populations of the world. Patients with BrS are considered symptomatic if they have history of aborted SCD, ventricular fibrillation (VF), sustained ventricular tachycardia (VT), or syncope. BrS usually presents during the third or fourth decade of life, and about 63% of patients are asymptomatic at diagnosis. However, syncope or major arrhythmic events (MAE) can occur at any age, or SCD may even present as the first event. BrS contributes towards sudden infant death syndrome, SCD in children, and is estimated to cause about 20% of all SCDs in individuals with anatomically normal cardiac structures.

Brugada syndrome pathogenesis management sudden cardiac death arrhythmic events primary electrical disease sudden cardiac arrest

1. Pathogenesis of BrS

BrS was previously described as an autosomal-dominant inherited disorder with incomplete penetrance, and absent or benign structural heart abnormalities [1][2]. The lack of significant structural heart disease in BrS patients may be visualized by echocardiography, angiography, or ventriculography [3][4]. However, magnetic resonance imaging in subgroups of patients with BrS revealed enlarged right ventricular (RV) volumes, increased RV outflow tract (RVOT) area, or mild RV wall motion abnormalities [5]. The pathomechanism observed in BrS patients involves depolarization and repolarization abnormalities, inflammation of myocytes, and fibrosis in RVOT and/or RV [6][7]. A recent study performed on whole hearts from deceased patients, whose SCD was accounted to BrS, showed biventricular myocardial fibrosis, especially in the epicardium of the RVOT [8]. RV myocardium in a number of patients with BrS type 1 ECG pattern have showed histological changes comparable to arrhythmogenic RV cardiomyopathy (ARVC), and indicate possible autoimmune causes of myocardial inflammation in BrS patients [6].
Genetic etiology, identified in about 14–34% cases, is primarily associated with sodium voltage-gated channel alpha subunit 5 (SCN5A) gene mutation affecting cardiac channels [6][9][10]. SCN5A gene encodes for the α-subunit of the sodium channels in the heart and mutations in the gene lead to reduced expression of Nav1.5 α-subunit proteins, loss of functional sodium channels, and impaired phase 0 action potential [2]. At present, other genes have been identified as susceptibility genes for BrS, and BrS is now considered an oligogenic or polygenic disease [6][11].
Currently, potassium, chloride, and calcium ion channels involved in the cardiac depolarization and repolarization process have also been described as associated with channelopathies caused by the dysfunction of regulatory proteins [12]. For example, excess outflow of potassium current during early repolarization or reduced inward current via calcium channels may contribute to BrS pathophysiology [12]. The reduced inward current flow of sodium in BrS patients may result in prolonged PR (PQ) interval, first degree atrioventricular block [13], slow cardiac conduction (intraventricular and His–Purkinje), phase 2 reentry and premature repolarization [12], low-amplitude and high-frequency electrical activity in RVOT epicardium (late potentials), and ventricular arrhythmias [7][14].
A recent study identified autoantibodies in the myocardium of BrS patients against cardiac proteins (α-actin, skeletal α-actin, connexin-43, keratin) and observed abnormal expression of Nav1.5 α-subunit proteins [6]. Another study reported distinct elevation (apolipoprotein E, clusterin, prothrombin, vitamin-D-binding protein, complement-factor H, voltage-dependent anion-selective channel protein 3, vitronectin) or reduction (alpha-1-antitrypsin, angiotensinogen, fibrinogen) in plasma proteome of BrS patients and relatives with SCN5AQ1118X gene mutation compared to their healthy family members without the gene mutation, as well as antithrombin-III post-translational modifications [15]. Figure 1 displays an overview of the pathomechanism processes in BrS.
/media/item_content/202204/625cc9f9c483cjcm-11-01912-g001.png
Figure 1. Overview of pathomechanisms involved in Brugada syndrome [2][6][7][12][13][15][16][17][18][19]. Abbreviations: AT—antithrombin; BrS—Brugada syndrome; Ca2+—calcium; ECG—electrocardiogram; K+—potassium; ICD—implantable cardioverter–defibrillator; Na+—sodium; SCD—sudden cardiac death; SCN5A—sodium voltage-gated channel alpha subunit 5; RV—right ventricle; RVOT—right ventricular outflow tract; VF—ventricular fibrillation; VT—ventricular tachycardia.

2. Diagnostics and Risk Stratification

The definitions of BrS can vary depending on the guidelines used. The European Society of Cardiology (ESC) guidelines proposes that any subject with spontaneous or drug-induced type 1 Brugada ECG pattern be classified as BrS [20]. However, some investigators suggest that this may lead to overdiagnosis, and specific symptoms or clinical data are required to confirm diagnosis [21][22]. Clinical, ECG, and laboratory markers have been found to be useful in diagnostics and risk stratification in diverse groups of patients [23][24][25][26][27][28][29][30][31][32][33]. Despite progress in SCD prevention, the optimal diagnostics and risk stratification in BrS are a major clinical challenge [34][35][36].

2.1. Diagnostics in BrS

The ESC definition of BrS diagnosis states that patients must display BrS ECG pattern with ST-segment elevation ≥ 2 mm in at least one lead (V1-V2) placed in the second, third, or fourth intercostal spaces [20]. This may appear spontaneously or following intravenous drug provocation with class Ia (ajmaline or procainamide) or class Ic (flecainide or pilsicainide) sodium channel blockers [20]. The BrS type 1 ECG pattern may also be induced by fever and exercise tests [2][6][16][37][38]. The unique ECG pattern is often short-lasting, and only depending on standard 12-lead ECG may lead to underdiagnosis of 65% patients, especially those who need modified high leads or drug provocation [6]. Therefore, prolonged cardiac monitoring might be highly valuable for diagnostic process [39]. When the Brugada ECG pattern is present without life-threatening arrhythmias or SCD, after exclusion of BrS, it is known as Brugada phenocopy [37].
The Shanghai scoring system for BrS diagnosis is based on ECG, family history, clinical symptoms, and genetics, and assigns a score of ≥3.5 for probable and/or definitive BrS (type 1 BrS ECG pattern–spontaneous or drug-induced), a score from 2 to 3 for possible BrS, and a score of <2 is nondiagnostic [6][40][41]. Additionally, a score of 3 was for fever-induced BrS type 1 ECG, a score of 2 for convertible drug-induced type 2 or 3 BrS ECG pattern, a score of 2 for definite BrS in family (first-/second-degree relative), a score of 0.5 for atrial fibrillation (AF) or atrial flutter in patients younger than age 30 ( no alternative etiology), and a score of 0.5 for probable pathologic genetic mutation which may lead to BrS [6]. SCN5A gene-mutation type and a BrS genetic risk score is associated with BrS phenotype in patients with spontaneous type 1 BrS ECG pattern or family members with SCN5A mutations [42]. Importantly, MRI studies have shown a correlation between maximal ECG ST segment elevation and maximal RVOT area in the presence of BrS type 1 ECG pattern [43].

2.2. Risk Stratification in BrS

ESC guidelines on ventricular arrhythmias and the prevention of SCD [20] recommend focusing on risk stratification and clinical decisions in the presence of previous SCA or documented spontaneous sustained VT, spontaneous diagnostic type 1 BrS ECG pattern, syncopal episodes, and inducible VF during programmed ventricular stimulation (PVS) (using two–three extrastimuli at two sites). According to the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society (AHA/ACC/HRS) recommendations, for additional risk stratification in asymptomatic BrS patients and in patients with spontaneous type 1 BrS ECG pattern, electrophysiological study (EPS) with PVS (using single and double extrastimuli) may be beneficial [44]. Wakamiya et al. evaluated the emphasis of arrhythmic syncope history or unexplained syncope and VF inducibility by ≤two extrastimuli during PVS according to new guidelines of the Japanese Circulation Society to help determine ICD indication in patients with BrS [45]. The research studied 234 BrS patients where 20% had VF history, 43% had syncope history, and 37% were asymptomatic at diagnosis [45]. Patients underwent PVS at RV apex or RVOT (1–3 extrastimuli) and mean follow-up was 6.9 ± 5.2 years [45]. The study underlined a less aggressive approach for PVS in BrS risk stratification.
Spontaneous type 1 BrS ECG pattern and syncopal episode history, fragmented QRS (fQRS), and ventricular effective refractory period (VRP) <200 milliseconds have been independently associated with ventricular arrhythmic events in BrS [46]. Moreover, prominent R wave (≥0.3 mV or R/q ≥ 0.75) in lead aVR (aVR sign) was identified to be associated with arrhythmic events in BrS [47]. Fever may precipitate both Brugada type 1 and 2 ECG patterns in patients who have normal baseline ECG [37], and predispose to the development of life-threatening ventricular arrhythmias and SCD [16]. However, a recent study indicated that asymptomatic patients with fever-induced type 1 BrS ECG pattern, negative family history of sudden death, and without spontaneous type 1 BrS ECG pattern are at low risk for future arrhythmic events [48].
Prolonged QRS complex duration, >120 milliseconds on standard 12-lead ECG due to slowed depolarization, was more pronounced in BrS patients expressing symptoms and may predict future MAE [7]. Moreover, T-peak to T-end (Tpe) intervals were identified as novel ECG markers in BrS patients for MAE prediction. High-risk BrS patients had longer Tpe interval in lead V1 and Tpeak-Tend/QT ratio compared to low-risk BrS patients [17]. Recently, based on 12-lead ECG data extracted from automated measurements in BrS patients, novel markers (i.e., ST slope) in predicting arrhythmic events in BrS were identified [19]. The authors stated that, using a weighted scoring system determined from QRS frontal axis, QRS duration, S wave duration and ST slope in lead I, as well as R wave duration in lead III, spontaneous VT/VF incidence may be predicted [19].
A new research performed on patients with drug-induced type 1 BrS ECG pattern who underwent PVS showed that a novel ECG marker dST-Tiso interval (the longest interval from V1-2 in the second, third, or fourth intercostal space) following ajmaline injection to be a significant predictor for the inducibility of ventricular arrhythmias (sustained or hemodynamically significant polymorphic VT of VF requiring direct current shock) [49]. The dST-Tiso interval lies in between the initiation and termination (at the isoelectric line) of the elevated coved ST-segment [49]. The dST-Tiso interval displayed adjusted OR 1.03 (95% CI: 1.01–1.04, p < 0.001) for ventricular arrhythmias inducibility. At the same time, dST-Tiso interval > 300 ms displayed 92.0% sensitivity, 90.2% specificity, 82.1% positive predictive value, and 95.8% negative predictive value for VT/VF inducibility prediction [49].
SCN5A gene variants may be important predictors of fatal events in BrS and valuable in risk stratification [50]. Loss-of-function SCN5A mutations have shown association with prolonged ECG conduction parameters (P wave or QRS durations) and increased occurrence of lethal arrhythmic events compared to the non-loss-of-function SCN5A mutations or SCN5A(−) BrS patients [50].
In BrS individuals, the presence of structural anomalies in the epicardium of the RVOT may contribute to arrhythmias [30]. Endocardial unipolar electroanatomical mapping technology may identify RVOT electrical abnormalities with VF inducibility during PVS and assist in BrS risk stratification [30][51]. Endocardial high-density electroanatomical mapping may permit BrS risk stratification in asymptomatic patients (referred for PVS) [30].
Published studies have discussed clinical risk score models in patients with BrS and were reviewed recently in detail [52]. Briefly, the Shanghai Brugada scoring system was predictive for malignant arrhythmic events among patients evaluated for BrS who were asymptomatic (n = 271), experienced syncopal episodes (n = 99), or had previous VF (n = 23) [40]. Importantly, there were no malignant arrhythmic events in patients with a score of 3 or less (possible or nondiagnostic BrS) [40]. In a multicentric study of 1613 BrS patients, 20% symptomatic (after aborted SCA or syncope) at diagnosis, researchers evaluated the Shanghai score of all patients and Sieira score of 461 patients (mean follow-up 6.5 ± 4.7 years) [53]. While both scoring systems identified arrhythmic events risk in patients with significantly elevated or reduced scores, risk stratification was challenging in intermediate-risk patients, e.g., Sieira score 2–4 [53]. Another multicenter international study of 1110 BrS patients developed a risk-score model for SCD or ventricular arrhythmias, and studied 16 proposed ECG/clinical markers for risk stratification and ICD therapy indication [54]. In a median follow-up of 5.33 years, 10.3% of patients had SCD or ventricular arrhythmias, and increased risk was associated with four factors: spontaneous type-1 BrS ECG pattern (14 points), possible arrhythmic syncope or early repolarization in peripheral leads (each 12 points), and type-1 BrS ECG pattern in peripheral leads (9 points) [54].

3. Treatment of Patients with BrS

According to the ESC guidelines, implantable cardioverter–defibrillator (ICD) placement is recommended for the management of BrS patients with aborted SCD or documented spontaneous sustained VT, and should be considered in patients with spontaneous BrS type 1 ECG and previous syncope history [20]. Decision on ICD implantation and approaches for the timeline of treatment in BrS patients should involve evaluation of the risk of ventricular arrhythmias, possible complications and adverse events such as inappropriate ICD shocks, and the impact on the patients’ quality of life [55][56]. Pharmacotherapy with quinidine or isoproterenol should be considered in BrS individuals for the treatment of recurrent VT/VF, such as in electrical storms [20][55]. Quinidine may also be an alternate treatment option for supraventricular arrhythmias or in patients with contraindications to ICD placement [20][55].
A relatively novel and promising approach to treatment in BrS patients is catheter ablation. Epicardial catheter ablation of the RVOT may be considered in patients with repetition of appropriate ICD shocks or previous electrical storms [20][57]. In a study of BrS patients with inducible VT/VF, catheter ablation of the epicardium of RVOT resulted in ventricular arrhythmias that were noninducible in majority of the patients, normalization of the BrS type 1 ECG pattern, and no recurrence of VT/VF in the long term follow-up [58]. In BrS individuals, lifestyle choices such as avoiding consumption of excessive alcohols or heavy meals, avoiding drugs or medications which may induce arrhythmias (http:// www.brugadadrugs.org, 26 March 2022), and immediate antipyretic treatment of fevers are of great clinical value [20].
Some of the published data on MAE risk stratification in BrS seems to be inconclusive or based on limited patient groups. In addition, conflicting evidence is present for the value of PVS during EPS in risk stratification [46][59]. Therefore, the researchers proposed a series of extensive umbrella reviews to investigate previous meta-analyses on BrS and evaluate current risk stratification options such as genetic testing, ECG, and PVS for MAE risk stratification, and clinical management guidance.

References

  1. Sieira, J.; Brugada, P. The definition of the Brugada syndrome. Eur. Heart J. 2017, 38, 3029–3034.
  2. Mizusawa, Y.; Wilde, A.A.M. Brugada syndrome. Circ. Arrhythm Electrophysiol. 2012, 5, 606–616.
  3. Antzelevitch, C.; Brugada, P.; Borggrefe, M.; Brugada, J.; Brugada, R.; Corrado, D.; Gussak, I.; LeMarec, H.; Nademanee, K.; Riera, A.R.P.; et al. Brugada syndrome: Report of the second consensus conference. Circulation 2005, 111, 659–670.
  4. Alings, M.; Wilde, A. “Brugada” syndrome. clinical data and suggested pathophysiological mechanism. Circulation 1999, 99, 666–673.
  5. Matusik, P.T.; Rydlewska, A.; Pudło, J.; Podolec, J.; Lelakowski, J.; Podolec, P. Brugada syndrome: New concepts and algorithms in management (RCD code: V 1A.1). J. Rare Cardiovasc. Dis. 2018, 3, 151–160.
  6. Chatterjee, D.; Pieroni, M.; Fatah, M.; Charpentier, F.; Cunningham, K.S.; Spears, D.A.; Chatterjee, D.; Suna, G.; Bos, J.M.; Ackerman, M.J.; et al. An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins. Eur. Heart J. 2020, 41, 2878A–2890A.
  7. Rattanawong, P.; Kewcharoen, J.; Techorueangwiwat, C.; Kanitsoraphan, C.; Mekritthikrai, R.; Prasitlumkum, N.; Puttapiban, P.; Mekraksakit, P.; Vutthikraivit, W.; Sorajja, D. Wide QRS complex and the risk of major arrhythmic events in Brugada syndrome patients: A systematic review and meta-analysis. J. Arrhythmia 2019, 36, 143–152.
  8. Miles, C.; Asimaki, A.; Ster, I.C.; Papadakis, M.; Gray, B.; Westaby, J.; Finocchiaro, G.; Bueno-Beti, C.; Ensam, B.; Basu, J.; et al. Biventricular myocardial fibrosis and sudden death in patients with Brugada syndrome. J. Am. Coll. Cardiol. 2021, 78, 1511–1521.
  9. Zhang, Z.-H.; Barajas-Martínez, H.; Xia, H.; Li, B.; Capra, J.A.; Clatot, J.; Chen, G.-X.; Chen, X.; Yang, B.; Jiang, H.; et al. Distinct features of probands with early repolarization and Brugada syndromes carrying SCN5A pathogenic variants. J. Am. Coll. Cardiol. 2021, 78, 1603–1617.
  10. Tse, G.; Lee, S.; Liu, T.; Yuen, H.C.; Wong, I.C.K.; Mak, C.; Mok, N.S.; Wong, W.T. Identification of novel SCN5A single nucleotide variants in Brugada syndrome: A territory-wide study from Hong Kong. Front. Physiol. 2020, 11, 574590.
  11. Barc, J.; Tadros, R.; Glinge, C.; Chiang, D.Y.; Jouni, M.; Simonet, F.; Jurgens, S.J.; Baudic, M.; Nicastro, M.; Potet, F.; et al. Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nat. Genet. 2022, 54, 232–239.
  12. Garcia-Elias, A.; Benito, B. Ion Channel Disorders and Sudden Cardiac Death. Int. J. Mol. Sci. 2018, 19, 692.
  13. Pranata, R.; Yonas, E.; Chintya, V.; Deka, H.; Raharjo, S.B. Association between PR Interval, First-degree atrioventricular block and major arrhythmic events in patients with Brugada syndrome—Systematic review and meta-analysis. J. Arrhythmia 2019, 35, 584–590.
  14. Saha, S.A.; Krishnan, K.; Madias, C.; Trohman, R.G. Combined right ventricular outflow tract epicardial and endocardial late potential ablation for treatment of Brugada storm: A case report and review of the literature. Cardiol. Ther. 2016, 5, 229–243.
  15. Di Domenico, M.; Cuda, G.; Scumaci, D.; Grasso, S.; Gaspari, M.; Curcio, A.; Oliva, A.; Ausania, F.; Di Nunzio, C.; Ricciardi, C.; et al. Biomarker discovery by plasma proteomics in familial Brugada Syndrome. Front. Biosci. 2013, 18, 564–571.
  16. Roterberg, G.; El-Battrawy, I.; Veith, M.; Liebe, V.; Ansari, U.; Lang, S.; Zhou, X.; Akin, I.; Borggrefe, M. Arrhythmic events in Brugada syndrome patients induced by fever. Ann. Noninvasive Electrocardiol. 2019, 25, 135–140.
  17. Zumhagen, S.; Zeidler, E.M.; Stallmeyer, B.; Ernsting, M.; Eckardt, L.; Schulze-Bahr, E. Tpeak–Tendinterval and Tpeak–Tend/QT ratio in patients with Brugada syndrome. Europace 2016, 18, 1866–1872.
  18. Tse, G.; Gong, M.; Li, C.K.H.; Leung, K.S.K.; Georgopoulos, S.; Bazoukis, G.; Letsas, K.P.; Sawant, A.C.; Mugnai, G.; Wong, M.C.S.; et al. T peak -T end, T peak -T end /QT ratio and T peak -T end dispersion for risk stratification in Brugada syndrome: A systematic review and meta-analysis. J. Arrhythmia 2018, 34, 587–597.
  19. Tse, G.; Lee, S.; Li, A.; Chang, D.; Li, G.; Zhou, J.; Liu, T.; Zhang, Q. Automated electrocardiogram analysis identifies novel predictors of ventricular arrhythmias in Brugada syndrome. Front. Cardiovasc. Med. 2021, 7, 399.
  20. Priori, S.G.; Blomström-Lundqvist, C.; Mazzanti, A.; Blom, N.; Borggrefe, M.; Camm, J.; Elliott, P.M.; Fitzsimons, D.; Hatala, R.; Hindricks, G.; et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the european society of cardiology (ESC). Endorsed by: Association for European paediatric and congenital cardiology (AEPC). Eur. Heart J. 2015, 36, 2793–2867.
  21. Pappone, C.; Santinelli, V. Brugada syndrome: Progress in diagnosis and management. Arrhythmia Electrophysiol. Rev. 2019, 8, 13–18.
  22. Antzelevitch, C.; Yan, G.-X.; Ackerman, M.J.; Borggrefe, M.; Corrado, D.; Guo, J.; Gussak, I.; Hasdemir, C.; Horie, M.; Huikuri, H.; et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Hear. Rhythm 2016, 13, e295–e324.
  23. Matusik, P.S.; Bryll, A.; Matusik, P.T.; Pac, A.; Popiela, T.J. Electrocardiography and cardiac magnetic resonance imaging in the detection of left ventricular hypertrophy: The impact of indexing methods. Kardiol. Pol. 2020, 78, 889–898.
  24. Kucharz, A.; Kułakowski, P. Fragmented QRS and arrhythmic events in patients with implantable cardioverter-defibrillators. Kardiol. Pol. 2020, 78, 1107–1114.
  25. Matusik, P.T. Biomarkers and cardiovascular risk stratification. Eur. Heart J. 2019, 40, 1483–1485.
  26. Matusik, P.T.; Małecka, B.; Lelakowski, J.; Undas, A. Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation. Clin. Res. Cardiol. 2020, 109, 426–434.
  27. Asvestas, D.; Tse, G.; Baranchuk, A.; Bazoukis, G.; Liu, T.; Saplaouras, A.; Korantzopoulos, P.; Goga, C.; Efremidis, M.; Sideris, A.; et al. High risk electrocardiographic markers in Brugada syndrome. Int. J. Cardiol. Heart Vasc. 2018, 18, 58–64.
  28. Okólska, M.; Łach, J.; Matusik, P.T.; Pająk, J.; Mroczek, T.; Podolec, P.; Tomkiewicz-Pająk, L. Heart Rate variability and its associations with organ complications in adults after fontan operation. J. Clin. Med. 2021, 10, 4492.
  29. Pruszczyk, P.; Skowrońska, M.; Ciurzyński, M.; Kurnicka, K.; Lankei, M.; Konstantinides, S. Assessment of pulmonary embolism severity and the risk of early death. Pol. Arch. Intern. Med. 2021, 131.
  30. Letsas, K.P.; Vlachos, K.; Conte, G.; Efremidis, M.; Nakashima, T.; Duchateau, J.; Bazoukis, G.; Frontera, A.; Mililis, P.; Tse, G.; et al. Right ventricular outflow tract electroanatomical abnormalities in asymptomatic and high-risk symptomatic patients with Brugada syndrome: Evidence for a new risk stratification tool? J. Cardiovasc. Electrophysiol. 2021, 32, 2997–3007.
  31. Lee, S.; Zhou, J.; Li, K.H.C.; Leung, K.S.K.; Lakhani, I.; Liu, T.; Wong, I.C.K.; Mok, N.S.; Mak, C.; Jeevaratnam, K.; et al. Territory-wide cohort study of Brugada syndrome in Hong Kong: Predictors of long-term outcomes using random survival forests and non-negative matrix factorisation. Open Heart 2021, 8, e001505.
  32. Lee, S.; Wong, W.T.; Wong, I.C.K.; Mak, C.; Mok, N.S.; Liu, T.; Tse, G. Ventricular Tachyarrhythmia Risk in Paediatric/Young vs. Adult Brugada Syndrome Patients: A Territory-Wide Study. Front. Cardiovasc. Med. 2021, 8, 671666.
  33. Tse, G.; Zhou, J.; Lee, S.; Liu, T.; Bazoukis, G.; Mililis, P.; Wong, I.C.K.; Chen, C.; Xia, Y.; Kamakura, T.; et al. Incorporating latent variables using nonnegative matrix factorization improves risk stratification in Brugada syndrome. J. Am. Heart Assoc. 2020, 9, e012714.
  34. Letsas, K.P.; Asvestas, D.; Baranchuk, A.; Liu, T.; Georgopoulos, S.; Efremidis, M.; Korantzopoulos, P.; Bazoukis, G.; Tse, G.; Sideris, A.; et al. Prognosis, risk stratification, and management of asymptomatic individuals with Brugada syndrome: A systematic review. Pacing Clin. Electrophysiol. 2017, 40, 1332–1345.
  35. Marsman, E.M.J.; Postema, P.G.; Remme, C.A. Brugada syndrome: Update and future perspectives. Heart 2021, 2020, 318258.
  36. Honarbakhsh, S.; Providência, R.; Lambiase, P.D.; Centre, S.B.H.B.H. Risk stratification in Brugada syndrome: Current status and emerging approaches. Arrhythmia Electrophysiol. Rev. 2018, 7, 79–83.
  37. Bernardo, M.; Tiyyagura, S.R. A case of type I and II Brugada phenocopy unmasked in a patient with normal baseline electrocardiogram (ECG). Am. J. Case Rep. 2018, 19, 21–24.
  38. Matusik, P.T.; Komar, M.; Podolec, J.; Karkowski, G.; Lelakowski, J.; Podolec, P. Exercise ECG unmasked Brugada sign: Manifestation of the risk of sports-associated sudden cardiac arrest (RCD code: V-1A.1). J. Rare Cardiovasc. Dis. 2017, 3, 92–97.
  39. Abe, A.; Kobayashi, K.; Yuzawa, H.; Sato, H.; Fukunaga, S.; Fujino, T.; Okano, Y.; Yamazaki, J.; Miwa, Y.; Yoshino, H.; et al. Comparison of late potentials for 24 hours between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy using a novel signal-averaging system based on holter ECG. Circ. Arrhythmia Electrophysiol. 2012, 5, 789–795.
  40. Kawada, S.; Morita, H.; Antzelevitch, C.; Morimoto, Y.; Nakagawa, K.; Watanabe, A.; Nishii, N.; Nakamura, K.; Ito, H. Shanghai Score system for diagnosis of brugada syndrome: Validation of the score system and system and reclassification of the patients. JACC Clin. Electrophysiol. 2018, 4, 724–730.
  41. Wilde, A.A.M. The Shanghai score system in Brugada syndrome: Using it beyond a diagnostic score. JACC Clin. Electrophysiol. 2018, 4, 731–732.
  42. Wijeyeratne, Y.D.; Tanck, M.W.; Mizusawa, Y.; Batchvarov, V.; Barc, J.; Crotti, L.; Bos, J.M.; Tester, D.J.; Muir, A.; Veltmann, C.; et al. SCN5A Mutation Type and a Genetic Risk Score Associate Variably with Brugada Syndrome Phenotype in SCN5A Families. Circ. Genom. Precis. Med. 2020, 13, e002911.
  43. Veltmann, C.; Papavassiliu, T.; Konrad, T.; Doesch, C.; Kuschyk, J.; Streitner, F.; Haghi, D.; Michaely, H.; Schoenberg, S.; Borggrefe, M.; et al. Insights into the location of type I ECG in patients with Brugada syndrome: Correlation of ECG and cardiovascular magnetic resonance imaging. Heart Rhythm 2012, 9, 414–421.
  44. Al-Khatib, S.M.; Stevenson, W.G.; Ackerman, M.J.; Bryant, W.J.; Callans, D.J.; Curtis, A.B.; Deal, B.J.; Dickfeld, T.; Field, M.E.; Fonarow, G.C.; et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American college of cardiology/American Heart association task force on clinical practice guidelines and the heart rhythm society. J. Am. Coll. Cardiol. 2018, 72, e91–e220.
  45. Wakamiya, A.; Kamakura, T.; Shinohara, T.; Yodogawa, K.; Murakoshi, N.; Morita, H.; Takahashi, N.; Inden, Y.; Shimizu, W.; Nogami, A.; et al. Improved risk stratification of patients with Brugada syndrome by the new Japanese circulation society guideline―A multicenter validation study. Circ. J. 2020, 84, 2158–2165.
  46. Priori, S.G.; Gasparini, M.; Napolitano, C.; Della Bella, P.; Ottonelli, A.G.; Sassone, B.; Giordano, U.; Pappone, C.; Mascioli, G.; Rossetti, G.; et al. Risk stratification in Brugada syndrome: Results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J. Am. Coll. Cardiol. 2012, 59, 37–45.
  47. Bigi, M.A.B.; Aslani, A.; Shahrzad, S. aVR sign as a risk factor for life-threatening arrhythmic events in patients with Brugada syndrome. Heart Rhythm 2007, 4, 1009–1012.
  48. Tsai, C.-F.; Chuang, Y.-T.; Huang, J.-Y.; Ueng, K.-C. Long-term prognosis of febrile individuals with right precordial coved-type ST-segment elevation Brugada pattern: A 10-year prospective follow-up study. J. Clin. Med. 2021, 10, 4997.
  49. Iacopino, S.; Chierchia, G.-B.; Sorrenti, P.; Pesce, F.; Colella, J.; Fabiano, G.; Campagna, G.; Petretta, A.; Placentino, F.; Filannino, P.; et al. dST-Tiso Interval, a novel electrocardiographic marker of ventricular arrhythmia inducibility in individuals with ajmaline-induced Brugada type I pattern. Am. J. Cardiol. 2021, 159, 94–99.
  50. Ishikawa, T.; Kimoto, H.; Mishima, H.; Yamagata, K.; Ogata, S.; Aizawa, Y.; Hayashi, K.; Morita, H.; Nakajima, T.; Nakano, Y.; et al. Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome. Eur. Heart J. 2021, 42, 2854–2863.
  51. Letsas, K.P.; Vlachos, K.; Efremidis, M.; Dragasis, S.; Korantzopoulos, P.; Tse, G.; Liu, T.; Bazoukis, G.; Niarchou, P.; Prappa, E.; et al. Right ventricular outflow tract endocardial unipolar substrate mapping: Implications in risk stratification of Brugada syndrome. Rev. Cardiovasc. Med. 2022, 23, 044.
  52. Chung, C.T.; Bazoukis, G.; Radford, D.; Coakley-Youngs, E.; Rajan, R.; Matusik, P.T.; Liu, T.; Letsas, K.P.; Lee, S.; Tse, G. Predictive risk models for forecasting arrhythmic outcomes in Brugada syndrome: A focused review. J. Electrocardiol. 2022, 72, 28–34.
  53. Probst, V.; Goronflot, T.; Anys, S.; Tixier, R.; Briand, J.; Berthome, P.; Geoffroy, O.; Clementy, N.; Mansourati, J.; Jesel, L.; et al. Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome. Eur. Heart J. 2021, 42, 1687–1695.
  54. Honarbakhsh, S.; Providencia, R.; Garcia-Hernandez, J.; Martin, C.A.; Hunter, R.J.; Lim, W.Y.; Kirkby, C.; Graham, A.J.; Sharifzadehgan, A.; Waldmann, V.; et al. A primary prevention clinical risk score model for patients with Brugada syndrome (BRUGADA-RISK). JACC: Clin. Electrophysiol. 2021, 7, 210–222.
  55. Letsas, K.P.; Georgopoulos, S.; Vlachos, K. Brugada syndrome:risk stratification and management corresponding author. J. Atr. Fibrillation 2016, 7, 79–83.
  56. Dereci, A.; Yap, S.C.; Schinkel, A.F.L. Meta-Analysis of clinical outcome after implantable cardioverter-defibrillator implantation in patients with Brugada syndrome. JACC Clin. Electrophysiol. 2019, 5, 141–148.
  57. Fernandes, G.C.; Fernandes, A.; Cardoso, R.; Nasi, G.; Rivera, M.; Mitrani, R.D.; Goldberger, J.J. Ablation strategies for the management of symptomatic Brugada syndrome: A systematic review. Heart Rhythm 2018, 15, 1140–1147.
  58. Nademanee, K.; Veerakul, G.; Chandanamattha, P.; Chaothawee, L.; Ariyachaipanich, A.; Jirasirirojanakorn, K.; Likittanasombat, K.; Bhuripanyo, K.; Ngarmukos, T. Arrhythmia/electrophysiology prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011, 123, 1270–1279.
  59. Asada, S.; Morita, H.; Watanabe, A.; Nakagawa, K.; Nagase, S.; Miyamoto, M.; Morimoto, Y.; Kawada, S.; Nishii, N.; Ito, H. Indication and prognostic significance of programmed ventricular stimulation in asymptomatic patients with Brugada syndrome. Europace 2020, 22, 972–979.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cardiac & Cardiovascular Systems
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Hasina Aziz
,
,
Paweł Matusik
View Times: 716
Entry Collection: Hypertension and Cardiovascular Diseases
Revisions: 4 times (View History)
Update Date: 18 Apr 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback